Skip to content

News: General News

Translate Bio Announces Pricing of Initial Public Offering

Translate Bio, Inc. (Nasdaq: TBIO) a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced the pricing of its initial public offering of 9,350,000 shares of its common stock at a price to the public of $13.00 per share, for total gross proceeds of approximately $121.6 million, before deducting underwriting discounts and commissions and expenses payable by Translate Bio.

Get the full story here